Gastric residual volume evaluation with ultrasonography after intravenous ondansetron and metoclopramide and neostigmine :A Double Blind Randomized clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190215042716N1

Enrollment

Registered

2020-01-11

Start date

2019-08-22

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric volume after gavage. Gastro-esophageal reflux disease without esophagitis

Interventions

Intervention 1: Intervention group 1: Ondansetron: Patients are given 8 mg intravenous ondansetron twice daily for 20 minutes and after five half-lives of medication their gastric volume is measured w

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients 18 to 80 years Patients hospitalized in ICU Patients with nasogastric tube or percutaneous gastrostomy tube

Exclusion criteria

Exclusion criteria: Do not place the nasal gastric tube in the stomach Prisoners Ileus Long-term fasting planning The remaining volume of the stomach is not examined by nurses for any reason

Design outcomes

Primary

Measure	Time frame
Size of gastric residual volume on ultrasound. Timepoint: Patients were studied after 5 half-lives of drug from the third day and 4 hours after morning gavage for the next 4 days. Method of measurement: Sonography device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Shafigh

Shahid Beheshti University of Medical Sciences

navid_shafigh2005@yahoo.com+98 21 2111 9279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026